| Literature DB >> 31548833 |
Ying'ai Cui1, Michiko Moriyama1, Kazuaki Chayama2, Yanhui Liu3, Chunmei Ya4, Basilua Andre Muzembo5, Md Moshiur Rahman6.
Abstract
BACKGROUND: Chronic hepatitis, mainly B or C, increases the risk of hepatocellular carcinoma and remains an emerging issue in the globe. China has high rates of liver cancer incidence and mortality in the world. To address such challenges, adequate management of chronic hepatitis is required. Self-management education is one alternative for improving the hepatitis patients' knowledge of the disease, mental health, and clinical management.This study aimed to examine the quality of life (QOL), psychological effects, and behavioral changes of a self-management program which allows continuity of care for chronic hepatitis B and C patients.Entities:
Keywords: China; Efficacy; Hepatitis; Patient education; Quality of life; Self-management; Telenursing
Year: 2019 PMID: 31548833 PMCID: PMC6749624 DOI: 10.1186/s12912-019-0366-7
Source DB: PubMed Journal: BMC Nurs ISSN: 1472-6955
Fig. 1Conceptual framework of the program
Fig. 2Recruitment, randomization and completion flowchart
Baseline characteristics and participant profiles
| Variable | Intervention group | Usual care group | |
|---|---|---|---|
| ( | ( | ||
| Characteristics | n (%) or | n (%) or | |
| mean ± SD | mean ± SD | ||
| Females | 15 (50.0) | 6 (20.0) | 0.029a* |
| Employed | 25 (83.3) | 22 (73.3) | 0.532a |
| Marital status: married | 26 (86.7) | 26 (86.7) | 1.000a |
| Living with another person | 28 (93.3) | 27 (90.0) | 1.000a |
| Age (years) | 33.2 ± 7.29 | 36.6 ± 10.56 | 0.152b |
| Subject profiles | |||
| Comorbidity | 25 (83.3) | 22 (73.3) | 0.532a |
| Diabetes mellitus | 27 (90.0) | 28 (93.3) | 1.000a |
| Recurrent history of liver disease in the past 2 years | 19 (63.3) | 14 (46.7) | 0.299a |
| Use of insulin | 29 (96.7) | 28 (93.3) | 1.000a |
| Treatment regimen | |||
| Antiviral medicine | 11 (36.7) | 9 (30.0) | 0.785a |
| Anti-fibrosis therapy | 13 (43.3) | 15 (50.0) | 0.796a |
| Immunotherapy | 4 (13.3) | 6 (20.0) | 0.731a |
| Liver protection therapy | 27 (90.0) | 28 (93.9) | 1.000a |
| Peg interferon | 11 (36.7) | 14 (46.7) | 0.601a |
| Types of hepatitis | |||
| Hepatitis B | 26 (86.7) | 26 (86.7) | 1.000a |
| Hepatitis C | 4 (13.3) | 4 (13.3) | |
SD Standard Deviation
*p < 0.05
a p value is based on Pearson’s chi-square test
b p value is based on t-test
Change in mean scores of CLDQ, CES-D and GSES in the intervention and usual care groups at 3 and 6 months follow-up
| Indicator | Time point | Two-way repeated measures analysis of variance (ANOVA) | Analysis of covariance (ANCOVA) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IV group | UC group | ||||||||||||
| n | Mean | SD | n | Mean | SD | Interaction | Within group | Between group | I - J | SE | |||
| CLDQ (QOL scale) | |||||||||||||
| Baseline | 30 | 135.2 | 20.6 | 26 | 140.0 | 21.2 | < 0.001 | < 0.001 | < 0.001 | −3.893 | 6.053 | 0.523 | |
| 3 M | 30 | 152.0 | 14.5 | 26 | 136.5 | 17.7 | 16.230 | 4.652 | 0.001 | ||||
| 6 M | 30 | 164.0 | 13.5 | 26 | 133.5 | 14.2 | 30.544 | 4.026 | < 0.001 | ||||
| CES-D (Depression scale) | |||||||||||||
| Baseline | 30 | 16.7 | 8.9 | 26 | 12.4 | 7.8 | 0.002 | < 0.001 | 0.537 | 3.891 | 2.439 | 0.117 | |
| 3 M | 30 | 11.8 | 6.3 | 26 | 11.8 | 5.8 | −0.267 | 1.749 | 0.879 | ||||
| 6 M | 30 | 9.5 | 5.1 | 26 | 11.0 | 5.3 | −2.203 | 1.499 | 0.148 | ||||
| GSES (Self – efficacy scale) | |||||||||||||
| Baseline | 30 | 2.4 | 0.6 | 26 | 2.5 | 0.6 | < 0.001 | 0.005 | 0.001 | −0.144 | 0.177 | 0.422 | |
| 3 M | 30 | 2.7 | 0.5 | 26 | 2.3 | 0.4 | 0.434 | 0.133 | 0.002 | ||||
| 6 M | 30 | 3.1 | 0.4 | 26 | 2.2 | 0.4 | 0.843 | 0.118 | < 0.001 | ||||
CLDQ Chronic Liver Disease questionnaires, CES-D the Center for Epidemiologic Depression scale, GSES General Self Efficacy Scale, IV Intervention group, SD Standard Deviation, I – J = Difference in average value, SE Standard Error, ANOVA Analysis of variance, ANCOVA Analysis of covariance, UC Usual care group, BL Base line, M month
*Analysis of covariance was carried out using gender as a covariate
**p values comparing the intervention group with the control group were obtained by multiple comparisons (Bonferroni’s correction)
Depressive tendency from baseline to the 6th month after discharge
| Group (n) | Baseline | 6th month | OR | 95% CI | |
|---|---|---|---|---|---|
| n (%) | n (%) | ||||
| IV (30) | 13 (43.3) | 5 (16.7) | 1.60 | 0.27–9.61 | 0.701 |
| UC (26) | 8 (30.8) | 5 (19.2) | Reference | Reference | Reference |
IV Intervention group, UC Usual care group, CI Confidence interval
*p value is based on Fisher’s exact test for count data
Changes in perceived cognition of illness at the 6th month after discharge in the intervention and usual care groups
| Mann-Whitney U-test | Analysis of covariance | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Measure | Baseline | 6th month | (ANCOVA) | |||||||
| n | Median | Interquartile range | Median | Interquartile range | I - J | SE |
| |||
| Perceived susceptibility | IV | 30 | 3.5 | 1–5 | 4.5 | 2–5 | 0.170 | 0.517 | 0.297 | 0.087 |
| UC | 26 | 3.5 | 2–5 | 4 | 2–5 | |||||
| Perceived severity | IV | 30 | 4 | 4–5 | 5 | 4–5 | 0.057 | 0.332 | 0.154 | 0.036 |
| UC | 26 | 4 | 4–5 | 5 | 3–5 | |||||
| Perceived benefit | IV | 30 | 4 | 3–4 | 4 | 3–5 | < 0.001 | 1.180 | 0.185 | < 0.001 |
| UC | 26 | 4 | 3–5 | 3 | 2–4 | |||||
| Perceived barriers | IV | 30 | 3 | 1–4 | 4 | 1–5 | < 0.001 | 1.233 | 0.245 | < 0.001 |
| UC | 26 | 3 | 2–4 | 2.5 | 1–4 | |||||
SE Standard Error, IV Intervention group, UC Usual care group, I – J = Difference in average value
Changes in health behaviors at the 6th month after discharge in the intervention and usual care groups
| Mann-Whitney U-test | Analysis of covariance | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Measure | Baseline | 6th month | (ANCOVA) | ||||||||
| n | Median | Interquartile range | n | Median | Interquartile range | I - J | SE | ||||
| Alcohol avoidance | IV | 30 | 6 | 1–6 | 30 | 6 | 4–6 | 0.001 | 0.910 | 0.210 | < 0.001 |
| UC | 26 | 5 | 3–6 | 19 | 4 | 4–6 | |||||
| Dietary habit | IV | 30 | 5 | 2–6 | 30 | 5 | 3–6 | 0.090 | 0.556 | 0.254 | 0.034 |
| UC | 26 | 5 | 3–6 | 19 | 4 | 3–6 | |||||
| Medication | IV | 30 | 6 | 5–6 | 30 | 5 | 2–6 | 0.298 | −0.275 | 0.284 | 0.338 |
| UC | 26 | 6 | 3–6 | 23 | 5 | 3–6 | |||||
| Prevention of fatigue | IV | 30 | 5 | 2–6 | 30 | 5 | 2–6 | 0.564 | 0.051 | 0.362 | 0.888 |
| UC | 26 | 5 | 3–6 | 19 | 4 | 2–6 | |||||
| Smoking cessation | IV | 30 | 6 | 1–6 | 30 | 6 | 1–6 | 0.134 | −0.054 | 0.527 | 0.919 |
| UC | 26 | 5 | 1–6 | 19 | 5 | 1–6 | |||||
| Stress management | IV | 30 | 6 | 1–6 | 30 | 5.5 | 3–6 | 0.065 | 0.579 | 0.270 | 0.037 |
| UC | 26 | 5 | 3–6 | 19 | 5 | 4–6 | |||||
SE Standard Error, IV Intervention group, UC Usual care group, I – J = Difference in average value